A comparative study to evaluate effects on HCV-RNA-PCR by current oral anti-viral therapy with Sofosbuvir and Daclatasvir in Hepatitis C patients with and without Diabetes Melitis in Pakistan

  • Kashif Rauf
  • Adnan Afzal
  • Fawad Hussain
  • Sadia Mohammad Azam Khan
  • Sikander Hayat Warraich
  • Kashif Zaheer
Keywords: Deviated nasal septum, nasal septum corrective surgery, sub-mucous resection, septoplasty.


Objective: To compare the effects of antiviral therapy such as sofosbuvir and daclatasvir in HCV patients which were diagnosed by HCV-RNA PCR without Diabetes Melitis.

Study Design:  Cross-sectional comparative study

Inclusion Criteria: HCV Positive patients after PCR test conformation between 20-75 years age.

Methodology: In this cross-sectional analysis total of 100 Hepatitis c infected patients selected, Sofosbuvir plus Daclatasvir treatment given for 03 months period. Different parameters were recorded such as Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, Hb levels, Serum ALT levels, and Serum ALP level. The statistical relation of the mentioned variables was analyzed through SPSS version 15.

Results: Out of a total of 100 patients, 47% (47) were males, 53% (53) were females, 44% (44) patients had a history of prior interferon therapy, 23% (23) patients were having low hemoglobin levels before starting treatment. Both groups completed oral antiviral treatment for 12 weeks & resulting data showed the equality of treatment on group B and group A as no decrease in hemoglobin (p=0.799), ALT normalization (p=1.000) & no rise in serum bilirubin (p=0.817) during 1st month of treatment was noted in both groups while the SVR noted of both groups also showed no significant difference to each other i.e. 92% & 94 % (p=0.696).

Conclusion:  This study concluded to monitor the anti-viral drug response against HCV patients.


1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015 Mar;65(2):87-108. https://doi.org/10.3322/caac.21262
2. Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. DOI: 10.1016/S0140-6736(14)61682-2
3. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El–Serag HB. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr 1;140(4):1182-8. https://doi.org/10.1053/j.gastro.2010.12.032
4. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C–related mortality in the United States, 1995‐2004. Hepatology. 2008 Apr;47(4):1128-35. https://doi.org/10.1002/hep.22165
5. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub S-R, Martini S, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016; 65:524-531.
6. Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C‐related liver disease and costs in Australia. Journal of gastroenterology and hepatology. 2014 Aug;29:1-9. https://doi.org/10.1111/jgh.12677
7. Tsai PC, Huang CF, Yu ML. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. Journal of hepatology. 2017 Feb 1;66(2):464. DOI: https://doi.org/10.1016/j.jhep.2016.10.035
8. Pol S. Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma. J Hepatol. 2016;65:734-40. DOI: http://dx.doi.org/10.1016/j.jhep.2016.05.045
9. Zeng QL, Li ZQ, Liang HX, Xu GH, Li CX, Zhang DW, Li W, Sun CY, Wang FS, Yu ZJ. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?. Journal of hepatology. 2016 Nov 1;65(5):1068-9. DOI: https://doi.org/10.1016/j.jhep.2016.07.029
10. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Annals of internal medicine. 2013 Mar 5;158(5_Part_1):329-37. DOI: 10.7326/0003-4819-158-5-201303050-00005
11. Tanveer, A., Khalid, S., Kazmi, S. and Faheem, S. (2013). End of Treatment Response in Chronic Hepatitis C Patients Treated with Interferon Alpha and Ribavirin. J Coll Physicians SurgPak, 23, 764-5 Tanveer A, Khalid S, Kazmi S, Faheem S. End of Treatment Response in Chronic Hepatitis C Patients Treated with Interferon Alpha and Ribavirin. J Coll Physicians Surg Pak. 2013; 23: 764-5.
12. Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and hepatitis C: a two-way association. Frontiers in endocrinology. 2015 Sep 14;6:134. https://doi.org/10.3389/fendo.2015.00134
13. D. P. Webster, P. Klenerman, and G. M. Dusheiko, “Hepatitis C,” Te Lancet, vol. 385, pp. 1124–1135, 2015.
14. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality?. Digestive and Liver Disease. 2016 Feb 1;48(2):105-11. https://doi.org/10.1016/j.dld.2015.10.016
15. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therapeutic advances in gastroenterology. 2014 May;7(3):131-40.doi: 10.1177/1756283X13515825
16. Chukkapalli V, Berger KL, Kelly SM, Thomas M, Deiters A, Randall G. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides. Virology. 2015 Feb 1;476:168-79. DOI:10.1016/j.virol.2014.12.018
17. Laperche S, Bouchardeau F, André-Garnier E, Thibault V, Roque-Afonso AM, Trimoulet P, Colimon R, Duverlie G, Leguillou-Guillemette H, Lunel F, Bouvier-Alias M. Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. Journal of clinical microbiology. 2011 Mar 1;49(3):1113-5. DOI: 10.1128/JCM.01511-10
18. Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Sutoh S, Abe H, Tsubota A, Aizawa Y. Impact of chronic hepatitis C virus genotype 1b infection on triglyceride concentration in serum lipoprotein fractions. International journal of molecular sciences. 2015 Sep;16(9):20576-94. https://doi.org/10.3390/ijms160920576
19. http://www.webmd.com/diabetes/guide/diagnosis-diabetes
20. Damon L, Andreadis C. Blood disorders. In: Lawrence M. Tierney, Stephen J, editors. Current medical diagnosis and treatment. 55th Ed. New York: McGraw-Hill; 2016: 495-541.
21. Szumilas M. Explaining odds ratios. Journal of the Canadian academy of child and adolescent psychiatry. 2010 Aug;19(3):227.
22. Wang CH, Sarnow PE, Siddiqui AL. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. Journal of virology. 1993 Jun 1;67(6):3338-44.
23. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. Journal of virology. 2001 Dec 15;75(24):12047-57. DOI: 10.1128/JVI.75.24.12047-12057.2001
24. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine. 2002 Sep 26;347(13):975-82. DOI: 10.1056/NEJMoa020047
25. Yi M, Lemon SM. 3′ nontranslated RNA signals required for replication of hepatitis C virus RNA. Journal of virology. 2003 Mar 15;77(6):3557-68. DOI: 10.1128/JVI.77.6.3557-3568.2003
26. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. Journal of virology. 2002 Jun 15;76(12):5974-84. DOI: 10.1128/JVI.76.12.5974-5984.2002
27. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. Journal of general virology. 2000 Jul 1;81(7):1631-48. https://doi.org/10.1099/0022-1317-81-7-1631
28. Moradpour D, Brass V, Gosert R, Wölk B, Blum HE. Hepatitis C: molecular virology and antiviral targets. Trends in molecular medicine. 2002 Oct 1;8(10):476-82. https://doi.org/10.1016/S1471-4914(02)02395-X
29. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997 Dec;26(S3):62S-5S. https://doi.org/10.1002/hep.510260711
30. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science. 1998 Oct 30;282(5390):938-41. DOI: 10.1126/science.282.5390.938
31. Brown Jr RS, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver transplantation. 2003 Nov;9(11):S10-3. https://doi.org/10.1053/jlts.2003.50244
How to Cite
Rauf K, Afzal A, Hussain F, Khan S, Warraich S, Zaheer K. A comparative study to evaluate effects on HCV-RNA-PCR by current oral anti-viral therapy with Sofosbuvir and Daclatasvir in Hepatitis C patients with and without Diabetes Melitis in Pakistan. JRMC [Internet]. 30Dec.2020 [cited 1Oct.2022];24(4):417-22. Available from: http://www.journalrmc.com/index.php/JRMC/article/view/1502